Publications & Patents


Research Publications

1. Chang KH, Nayak R, Roy S, Perumbeti A, Ficker AM, Bezold K, Pirman M, Dunn SK, Starnes J, Loberg A, Zhou X, Inagami T, Zheng Y, Malik P, Cancelas JA. Vasculopathy associated hyperangiotensinemia mobilizes hematopoietic stem cells/progenitors through endothelial AT2R and cytoskeletal dysregulation. Nat Commun 2015 Jan 9;6:5914. doi: 10.1038/ncomms6914. PMID: 25574809 PMC4293039 [Available on 2015/7/9]

2. Chang KH, Sengupta A, Nayak RC, Duran A, Lee SJ, Pratt RG, Wellendorf AM, Watkins M, Gonzalez-Nieto D, Aronow BJ, Starczynowski DT, Civitelli R, Diaz-Meco MT, Moscat J, Cancelas JA. p62 is required to retain short-term repopulating and myeloid progenitor cells through inhibition of IKK/NF-κB/Ccl4 signaling at the bone marrow macrophage-osteoblast niche. Cell Rep Dec 24 2014;9(6):2084-97. PMC4277497 www.sciencedirect.com/science/article/pii/S2211124714009978

3. Cancelas JA, Padmanabhan A, Le T, Ambruso DR, Rugg N, Worsham DN, Pinkard SL, Graminske S, Buck J, Goldberg J, Bill J. Spectra Optia granulocyte apheresis collections result in higher collection efficiency of viable, functional neutrophils in a randomized, crossover, multicenter trial. Transfusion, epub 10 Nov 2014.  doi: 10.1111/trf.12907. PMID: 25382805

4. Dumont LJ*, Cancelas JA*, Maes LA, Rugg N, Whitley P, Herschel L, Siegel AH, Szczepiorkowski ZM, Hess JR, Zia M. Overnight, room-temperature hold of whole blood followed by 42-day storage of RBCs in additive solution-7. *co-first authors. Transfusion 2014, Epub Sep 19. doi: 10.1111/trf.12868. PMID: 25234026

5. Cancelas JA, Dumont LJ, Maes LA, Rugg N, Herschel L, Whitley PH, Szczepiokowski ZM, Siegel AH, Hess JR, Zia M. Additive solution-7 (AS-7) reduces the red blood cell cold-storage lesion. Transfusion 2014, Epub Sep 19. doi: 10.1111/trf.12867. PMID: 25233911

6. Dumont LJ*, Cancelas JA*, Maes LA, Rugg N, Whitley P, Herschel L, Siegel AH, Szczepiorkowski ZM, Hess JR, Zia M. The bioequivalence of frozen plasma prepared from whole blood held overnight at room temperature compared to fresh-frozen plasma prepared within eight hours of collection. *co-first authors. Transfusion 2014, Epub Sep 19. doi: 10.1111/trf.12864. PMID: 25233805

7. Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Christie S, Chen X, Rao DS, Grimes HL, Komurov K, Weirauch MT, Cancelas JA, Maciejewski JP, Starczynowski DT. Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network. Cell Rep 2014 Sep 11;8(5):1328-38. PMC4237069 http://www.sciencedirect.com/science/article/pii/S2211124714006652

8. Privette Vinnedge LM, Benight NM, Wagh PK, Pease NA, Nashu MA, Serrano-Lopez J, Adams AK, Cancelas JA, Waltz SE, Wells SI. The DEK oncogene promotes cellular proliferation through paracrine Wnt signaling in Ron receptor-positive breast cancers. Oncogene. Jul 2014;28(3):114–25. PMID: 24954505 PMC4275425 [Available on 2015/12/23]

9. Mock DM, Widness JA, Veng-Pedersen P, Strauss RG, Cancelas JA, Cohen RM, Lindsell CJ, Franco RS. Measurement of post-transfusion red cell survival with the biotin label. Transfusion Med Rev Epub Apr 5, 2014. PMID: 24969019 PMCID: PMC4122272 [Available on 2015/7/1]

10. Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, Jordan CT, Aronow BJ, Marcucci G, Bhat B, Gebelein B, Grimes HL. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. J Clin Invest. 2014 Jan 2;124(1):222-36. PMC3871218 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871218/

11. Tidwell T, Wechsler J, Nayak RC, Trump L, Salipante SJ, Cheng JC, Donadieu J, Glaubach T, Corey SJ, Grimes HL, Lutzko C, Cancelas JA, Horwitz MS. Neutropenia-associated ELANE mutations disrupting translation initiation produce novel neutrophil elastase isoforms. Blood 2014;123(4):562-569. PMC3901069 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901069/

12. Taniguchi Ishikawa E*, Chang KH*, Nayak R, Olsson HA, Ficker AM, Dunn SK, Madhu MN, Sengupta A, Whitsett JA, Grimes HL, Cancelas JA. Klf5 controls bone marrow homing of stem cells and progenitors through Rab5-mediated membrane β1/β2-integrin expression. Nat Commun 2013 Apr 3;4:art. No. 1660. doi: 10.1038/ncomms2645. (*equal contributing authors) PMC3627399 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627399/

13. Raman R, Kumar RS, Hinge A, Kumar S, Nayak R, Xu J, Szczur K, Cancelas JA, Filippi MD. p190-B RhoGAP regulates the functional composition of the mesenchymal microenvironment. Leukemia 2013;27(11):2209-19. PMC3919554 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830525/

14. Nayak RC, Chang K-H, Vaitinadin N-S, Cancelas JA. Rho GTPases control specific cytoskeleton dependent functions of hematopoietic stem cells. [Review] Immunol Rev 2013 Nov;256(1):255-268. PMC3830525 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3830525/

15. Zhou X, Florian MC, Arumugam P, Chen X, Cancelas JA, Lang R, Malik P, Geiger H, Zheng Y. RhoA GTPase controls cytokinesis and programmed necrosis of hematopoietic progenitors. J Exp Med 2013 Oct 21; 210(11):2371-2385. PMID: 2401377, PMCID: 3804933.

16. Mayes DA, Rizvi TA, Titus-Mitchell H, Oberst R, Ciraolo GM, Vorhees CV, Robinson AP, Miller SD, Cancelas JA, Stemmer-Rachamimov AO, Ratner N. Nf1 loss and Ras hyperactivation in oligodendrocytes induce NOS-driven defects in myelin and vasculature. Cell Rep 2013 Sep 26;4(6):1197-212. PMC3982616 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982616/

17. Guo F, Zhang S, Grogg M, Cancelas JA, Varney ME, Starczynowski DT, Du W, Yang J-Q, Liu W, Thomas G, Kozma S, Pang Q, Zheng Y. Mouse gene targeting reveals an essential role of mTOR in hematopoietic stem cell engraftment and hematopoiesis. Haematologica. 2013;98(9):1353-8. PMC3762090 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762090/

18. Pamphilon D, Selogie E, McKenna D, Cancelas(-Peres (sic)) JA, Szczepiorkowski ZM, Sacher R, McMannis J, Eichler H, Garrietsen H, Takanashi M, Van de Watering L, Stroncek D, Reems J-A. Current practices and prospects for standardization of the hematopoietic colony-forming-unit (CFU) assay: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Cytotherapy 2013 Mar;15(3):255-262. PMID: 23579058

19. Prada CE, Jousma E, Rizvi TA, Wu J, Dunn RS, Mayes DA, Cancelas JA, Dombi E, Kim MO, West BL, Bollag G, Ratner N. Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition. Acta Neuropathol 2013 Jan;125(1):159-68. PMC3547628 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547628/

20. Dumont LJ*, Cancelas JA*, Dumont DF, Siegel AH, Szczepiorkowski ZM, Rugg R, Pratt PG, Worsham DN, Hartman EL, Dunn SK, O’Leary M, Ransom JH, Michael RA, Macdonald VW. A randomized controlled trial evaluating recovery and survival of 6% dimethyl sulfoxide-frozen autologous platelets in healthy volunteers. Transfusion 2013 Jan;53(1):128-37. (*equal contributing authors) PMID: 22671278

21. Dumont LJ*, Cancelas JA*, Graminske S, Friedman KD, Vassallo RR, Whitley PH, Rugg N, Dumont DF, Herschel L, Siegal AH, Szczepiorkowski ZM, Fender L, Razatos A. In vitro and in vivo quality of leukocyte-reduced apheresis platelets stored in a new platelet additive solution. Transfusion 2013, May;53(5):972-80. (*equal contributing authors) PMID: 22882530

22. Taniguchi Ishikawa E, Cancelas JA. Lack of communication rusts and ages stem cells. Cell Cycle 2012 Sep 1;11(17):3149-3150. PMC3466507 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466507/

23. Geiger H, Pawar SA, Kerschen EJ, Nattamai KJ, Hernandez I, Liang HP, Fernández JA, Cancelas JA, Ryan MA, Kustikova O, Schambach A, Fu Q, Wang J, Fink LM, Petersen KU, Zhou D, Griffin JH, Baum C, Weiler H, Hauer-Jensen M. Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med Jul 2012;18(7):1123-9. PMC3491776 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491776/

24. Chang KH, Sanchez-Aguilera A, Shen S, Sengupta A, Madhu MN, Ficker AM, Dunn SK, Kuenzi AM, Anrett JL, Santho RA, Agirre X, Perentesis JP, Deininger MW, Zheng Y, Bustelo XR, Williams DA, Cancelas JA. Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation and survival. Blood 2012 Jul 26;120(4):800-11. PMC3412345 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412345/

25. Taniguchi Ishikawa E, Gonzalez-Nieto D, Ghiaur G, Dunn SK, Ficker AM, Murali B, Madhu M, Gutstein DE, Fishman GI, Barrio LC, Cancelas JA. Connexin-43 prevents hematopoietic stem cell senescence through transfer of reactive oxygen species to bone marrow stromal cells. Proc Natl Acad Sci USA 2012 Jun 5;109(23):9071-6. PMC3384185 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384185/

26. Konstantinidis DG, Pushkaran S, Johnson JF, Cancelas JA, Manganaris S, Harris CE, Williams DA, Zheng Y, Kalfa TA. Signaling and cytoskeletal requirements in erythroblast enucleation. Blood 2012 Jun 21;119(25):6118-27. PMC3383020 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3383020/

27. Gonzalez-Nieto D, Li L, Köhler A, Ghiaur G, Ishikawa E, Sengupta A, Madhu M, Arnett J, Santho RA, Dunn S, Fishman G, Gutstein D, Civitelli R, Barrio L, Gunzer M, Cancelas J. Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors. Blood 2012 May 31;119(22):5144-54. PMC3369607 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3369607/

28. Sengupta A, Ficker AM, Dunn SK, Madhu M, Cancelas JA. Bmi1 reprograms chronic myelogenous leukemia B-lymphoid progenitors to become B-ALL-initiating cells. Blood 2012 Jan12;119(2):494-502. PMID: 22101899, PMCID: 3257014 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3257014

29. Cancelas JA, Sengupta A. A conundrum in mammalian hematopoietic stem cell polarity. Cell Cycle 2011 Dec 15;10(24):4191-2. (Editorial). PMID: 22157228

30. Cancelas JA. On how Rac controls hematopoietic stem cell activity. Transfusion 2011 Nov;51 (Suppl 4):153S-9S. PMC3308685 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3308685/

31. Cancelas JA, Dumont LJ, Rugg N, Szczepiorkowski ZM, Herschel L, Siegel A, Pratt PG, Worsham DN, Erickson A, Propst M, North A, Sherman CD, Mufti NA, Reed WF, Corash L. Stored red blood cell viability is maintained after treatment with a second generation S-303 pathogen inactivation process. Transfusion 2011 Nov;51(11):2367-76. PMID: 21569044

32. Cancelas JA, Rugg N, Pratt PG, Worsham DN, Pehta JC, Banks K, Davenport RD, Judd WJ. Infusion of P-Capt prion filtered red cell products demonstrate acceptable in vivo viability and no evidence of neoantigen formation. Transfusion 2011 Oct;51(10):2228-36. PMID: 21492178

33. Cancelas JA, Rugg N, Fletcher D, Pratt, PG, Worsham DN, Dunn SK, Marschner S, Reddy HL, Goodrich RP. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood. Transfusion 2011 Jul;51(7):1460-8. PMID: 21275998

34. Shang X, Cancelas JA, Li L, Guo F, Liu W, Johnson JF, Ficker A, Daria D, Geiger H, Ratner N, Zheng Y. R-Ras and Rac GTPase crosstalk regulates hematopoietic progenitor cell migration, homing and mobilization. J Biol Chem 2011 Jul 8;286(27):24068-78. PMC3129188 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129188/

35. Mayes DA, Rizvi TA, Cancelas JA, Kolasinski NT, Ciraolo GM, Stemmer-Rachamimov AO, Ratner N. Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation. Cancer Res 2011 Jul 1;71(13):4675-85. PMC3464476 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464476/

36. Sengupta A, Duran A, Ishikawa E, Florian MC, Dunn SK, Ficker AM, Leitges M, Geiger H, Diaz-Meco M, Moscat J, Cancelas JA. Atypical protein kinase C (aPKCζ and aPKCλ) is dispensable for mammalian hematopoietic stem cell activity and blood formation. Proc Natl Acad Sci USA 2011 Jun 14;108(24):9957-62. PMC3116405 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116405/

37. Cardigan R, van der Meer PF, Pergande C, Cookson P, Baumann-Baretti B, Cancelas JA, Devine D, Gulliksson H, Vassallo R, de Wildt-Eggen J. Coagulation factor content of plasma produced from whole blood stored for 24 hours at ambient temperature: results from an international multicenter BEST Collaborative study. Transfusion 2011 Jan;51(Suppl 1):50S–57S. PMID: 21223296

38. van der Meer PF, Cancelas JA, Vassallo RR, Rugg N, Einarson M, Hess JR. Evaluation of the overnight hold of whole blood at room temperature, before component processing: platelets (PLTs) from PLT-rich plasma. Transfusion 2011 Jan;51(Suppl 1):45S–49S. PMID: 21223295,

39. van der Meer PF, Cancelas JA, Cardigan R, Devine DV, Gulliksson H, Sparrow RL, Vassallo RR, de Wildt-Eggen J, Baumann-Baretti B, Hess JR, for the BEST Collaborative. Evaluation of overnight hold of whole blood at room temperature before component processing: effect of red blood cell (RBC) additive solutions on in vitro RBC measures. Transfusion 2011 Jan;51(Suppl 1):15S–24S. PMID: 21223291

40. Sengupta A, Cancelas JA. Cancer stem cells: a stride towards cancer cure? J Cell Physiol 2010 Oct;225(1):7-14. PMID: 20458736

41. Ryan MA, Nattamai KJ, Xing E, Schleimer D, Daria D, Sengupta A, Köhler A, Liu W, Gunzer M, Jansen M, Ratner N, Le Cras TD, Waterstrat A, Van Zant G, Cancelas JA, Zheng Y, Geiger H. Pharmacological inhibition of EGFR signaling enhances G-CSF induced hematopoietic stem cell mobilization. Nat Med 2010 Oct;16(10):1141-6. PMID: 20871610

42. Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood 2010 Jul 8;116(1):81-4. PMC2904584 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904584/

43. Yamada Y, Cancelas JA. FIP1L1/PDGFR alpha-associated systemic mastocytosis. Int Arch Allergy Immunol 2010;152 Suppl 1:101-5. PMC 2917731 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917731/

44. McAteer MJ, Dumont LJ, Cancelas J, Rugg N, Vassallo R, Whitley P, Graminske S, Friedman K. Multi-institutional randomized control study of haemolysis in stored red cell units prepared manually or by an automated system. Vox Sang 2010 Jul 1;99(1):34-43. PMID: 20202178

Complete List of Published Work for Dr. Cancelas:   http://www.ncbi.nlm.nih.gov/sites/myncbi/jose.cancelas.1/bibliography/41148934/public/?sort=date&direction=descending


Patents

Prolonged Storage of Red Blood Cells and Composition   
Hess JR, Greenwalt TJ

Novel additive solutions that are useful for the storage of human red blood cells (RBCs) under refrigerated conditions. Also, a method of using the additive solutions in an appropriate volume to preserve RBCs at about 1 to 6°C for up to 10 weeks. The solutions and processes allow the viable storage of human RBCs for an extended period of time in a solution which is directly infusible in humans.
Issue Date: November 21, 2000 US Patent # 6150085

Preservation and Shelf Life Extension of Blood Cells  

Hess JR, Greenwalt TJ

Preservative solutions that extend the useful shelf-life of red cells from the current 6 to 12 weeks. This intellectual property is shared by the US Army and the University of Cincinnati. Implementation is expected to save 600,000 units from outdating annually, to reduce seasonal shortages of blood, and to make autologous donor programs more efficient.
Issue Date: November 20, 2001 US Patent # 6447987

Compositions Substantially Free of Sodium Chloride and Methods For The Storage of Red Blood Cells    
Hess JR, Greenwalt TJ

Composition of a solution for storage of red blood cells consisting essentially of: adenine; dextrose; a non-metabolizable membrane-protectant sugar; and a specifically defined pH buffering system. Improved methods for preserving red blood cells and methods for increasing the viability, membrane retention, and recoverability while suppressing apoptosis, hemolysis, and post-reinfusion clearance of stored red blood cells which utilize the novel compositions.
Issue Date: April 29, 2014 US Patent # 8709707